We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Abzena | LSE:ABZA | London | Ordinary Share | GB00BN65QN46 | ORD GBP0.002 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 15.75 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMABZA
RNS Number : 2387P
Abzena PLC
15 November 2016
Abzena plc
Notice of half year results
Cambridge, UK, 15 November 2016 - Abzena plc (AIM: ABZA, 'Abzena' or the 'Group'), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, will be publishing its half year results for the six months to 30 September 2016 on Wednesday, 30 November 2016.
A presentation for analysts will be held at 9.30am on 30 November 2016 at the offices of Instinctif Partners, 65 Gresham Street, London EC2V 7NQ.
Enquiries:
Abzena plc John Burt, Chief Executive Officer Julian Smith, Chief Financial Officer +44 1223 903498 Numis (Nominated Adviser and Broker) Clare Terlouw / Paul Gillam +44 20 7260 1000 N+1 Singer (Joint Broker) Aubrey Powell / Liz Yong +44 20 7496 3000 Instinctif Partners +44 20 7457 2020 Melanie-Toyne Sewell / Rozi abzena@instinctif.com Morris
About Abzena
Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products, a growing area that requires specialist knowledge and expertise. The Group has a global customer base which includes the majority of the top 20 biopharmaceutical companies as well as large and small biotech companies and academic groups.
The term "Abzena inside" is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on "Abzena inside" products.
Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA).
Hot Features
Premium
-- Immunogenicity assessment, protein engineering to create humanized antibodies and deimmunised therapeutic
proteins, and cell line development for manufacture.
-- Contract process development and manufacture of biopharmaceuticals, including monoclonal antibodies, recombinant
proteins, vaccines, and gene therapy and cell therapy products, for preclinical and clinical studies.
-- Proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for
optimizing the therapeutic properties of biopharmaceuticals.
-- Contract chemistry and bioconjugation business focused on ADCs and is establishing the capability to manufacture
ADCs to GMP standards.
For more information, please see www.abzena.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORDMMMMZKGGVZM
(END) Dow Jones Newswires
November 15, 2016 07:42 ET (12:42 GMT)
1 Year Abzena Chart |
1 Month Abzena Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
